3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
2
Terminated
1
Recruiting
1
Not yet recruiting
1
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Conditions
Melanoma
4
Thyroid Carcinoma, Anaplastic
3
Neoplasms
3
Glioma
3
Colorectal Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Thyroid Neoplasms
1
Spinocerebellar Degenerations
1
Solid Tumor
1
Skin Neoplasms
1
Sexual Dysfunction, Physiological
1
Refractory Differentiated Thyroid Gland Carcinoma
1
Recurrence
1
Rare Malignant Neoplasm
1
Oligodendroglioma
1
Neurofibromatosis 1
1
Neurofibroma, Plexiform
1
Neurocytoma
1
Neuroblastoma
1
Neoplasm Metastasis
1
Multiple Myeloma
1
Lymphoma, Non-Hodgkin
1
Lung Neoplasms
1
Locally Advanced Thyroid Gland Carcinoma
1
Histiocytosis, Langerhans-Cell
1
Hematologic Neoplasms
1
Glioblastoma
1
Ganglioneuroma
1
Ganglioglioma
1
Eunuchism
1
Interventions
Cyclophosphamide
22
fludarabine
20
venetoclax
8
Whole-Body Irradiation
8
Mycophenolic Acid
8
Standard of Care
6
Mesna
6
Melphalan
6
Azacitidine
6
fludarabine phosphate
5
Sirolimus
5
thymoglobulin
4
Thiotepa
4
Tacrolimus
4
Specimen Handling
4
Filgrastim
4
Cytarabine
4
entrectinib
3
daratumumab
3
cobimetinib
3
alectinib
3
Vemurafenib
3
Surveys and Questionnaires
3
Rituximab
3
Practice Guidelines as Topic
3
Palliative Care
3
Granulocyte Colony-Stimulating Factor
3
Busulfan
3
Bortezomib
3
Blood Specimen Collection
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Hematologic Neoplasms
×
dabrafenib
×
Clear all
NCT05159245
2024-07-15
FINPROVE
Helsinki University Central Hospital
Phase 2
Recruiting
250 enrolled